Elevated energy expenditure in cancer patients with solid tumours
- PMID: 1826450
- DOI: 10.1016/0277-5379(91)90050-n
Elevated energy expenditure in cancer patients with solid tumours
Abstract
Cancer patients (n = 106) and non-cancer subjects (n = 96) were classified as weight stable (n = 70) or weight-losing (n = 132). Cancer patients had elevated resting energy expenditure (REE) compared with either weight-losing (23.6 [0.4] vs. 20.5 [0.5] kcal/kg per day, P less than 0.001) or weight-stable controls (22.0 [0.6] vs. 17.9 [0.4], P less than 0.001). Cancer patients had increased fat oxidation irrespective of weight loss (1.24 [0.07] vs. 0.87 [0.04] mg/kg per min; 1.07 [0.04] vs. 0.78 [0.04], P less than 0.001). Elevated energy expenditure was counter-regulated by a decrease in thyroid hormones. Abnormal liver function had no impact on REE in either group. Heart rate was the most powerful factor for prediction of high energy expenditure in both patients and controls. Elevated energy expenditure was related to the increased heart rate in cancer patients in a significantly higher proportion than that in controls. Increased metabolic rate is a significant component behind weight loss in cancer disease, independent of malnutrition and an elevated adrenergic state may be a likely explanation.
Comment in
-
Cancer cachexia revisited: old problems and new perspectives.Eur J Cancer. 1991;27(1):1-3. doi: 10.1016/0277-5379(91)90046-g. Eur J Cancer. 1991. PMID: 1826430 No abstract available.
Similar articles
-
Dietary intake and resting energy expenditure in relation to weight loss in unselected cancer patients.Int J Cancer. 2001 Aug 1;93(3):380-3. doi: 10.1002/ijc.1332. Int J Cancer. 2001. PMID: 11433403
-
Evaluation of mechanisms behind elevated energy expenditure in cancer patients with solid tumours.Eur J Clin Invest. 1993 Jan;23(1):46-52. doi: 10.1111/j.1365-2362.1993.tb00716.x. Eur J Clin Invest. 1993. PMID: 8383058 Clinical Trial.
-
Beta-adrenoceptor activity and resting energy metabolism in weight losing cancer patients.Eur J Cancer. 2000 Feb;36(3):330-4. doi: 10.1016/s0959-8049(99)00273-7. Eur J Cancer. 2000. PMID: 10708933 Clinical Trial.
-
Resting energy metabolism and anticancer treatments.Curr Opin Clin Nutr Metab Care. 2018 May;21(3):145-151. doi: 10.1097/MCO.0000000000000457. Curr Opin Clin Nutr Metab Care. 2018. PMID: 29369114 Review.
-
Measuring cachexia-diagnostic criteria.Ann Palliat Med. 2019 Jan;8(1):24-32. doi: 10.21037/apm.2018.08.07. Epub 2018 Sep 7. Ann Palliat Med. 2019. PMID: 30525765 Review.
Cited by
-
Cardiac Remodeling in Cancer-Induced Cachexia: Functional, Structural, and Metabolic Contributors.Cells. 2022 Jun 15;11(12):1931. doi: 10.3390/cells11121931. Cells. 2022. PMID: 35741060 Free PMC article. Review.
-
Diverging metabolic programmes and behaviours during states of starvation, protein malnutrition, and cachexia.J Cachexia Sarcopenia Muscle. 2020 Dec;11(6):1429-1446. doi: 10.1002/jcsm.12630. Epub 2020 Sep 28. J Cachexia Sarcopenia Muscle. 2020. PMID: 32985801 Free PMC article. Review.
-
Weight gain, metabolic syndrome, and breast cancer recurrence: are dietary recommendations supported by the data?Int J Breast Cancer. 2012;2012:506868. doi: 10.1155/2012/506868. Epub 2012 Sep 24. Int J Breast Cancer. 2012. PMID: 23050155 Free PMC article.
-
Cancer cachexia: mechanisms and clinical implications.Gastroenterol Res Pract. 2011;2011:601434. doi: 10.1155/2011/601434. Epub 2011 Jun 13. Gastroenterol Res Pract. 2011. PMID: 21760776 Free PMC article.
-
Combination of telmisartan with cisplatin controls oral cancer cachexia in rats.Biomed Res Int. 2013;2013:642848. doi: 10.1155/2013/642848. Epub 2013 Dec 5. Biomed Res Int. 2013. PMID: 24381940 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources